Tetanus Immunity in Individuals Aged 50 Years or Older in Kashan, Iran
,
Abstract
Tetanus can be only prevented by vaccination because immunity against this disease is rarely acquired, even by natural infections. To maintain long-term protective immunity against tetanus, booster immunization is essential for adolescents and adults. Most hospitalized cases and virtually all deaths occur in people over 60 years of age. The purpose of this study was to investigate the degree of protective tetanus immunity among 50 years of age and older people in Kashan city, Iran. This cross-sectional study carried out on 180 randomly individuals aged 50 years or older who were visiting a central laboratory for health examinations in 2008. Participants' serum levels of tetanus antitoxin were measured by enzyme linked immunosorbent assay. A standard questionnaire was used to collect demographic data and information about risk factors. The prevalence of protective tetanus immunity in various age groups was described and sociodemographic factors that potentially influenced the degree of tetanus immunity were analyzed. Overall, 180 persons were included. Of these, 72 (40%) had never received a toxoid booster, while 47 (26.1%) had received a booster at least once. Among all participants, 30 (16.7%) had protective tetanus antitoxin levels (≥ 0.11 IU/mL), and 34 (18.9%) had protective antitoxin levels without the need of an immediate booster ≥0.51 IU/mL. Among 86 participants aged >60 years, 6 (7%) had protective antitoxin levels ≥0.1-1 IU/mL, and 5(5.8%) had protective antitoxin levels ≥1 IU/mL. Male gender and prior receipt of toxoid booster(s) were associated with protective tetanus immunity. Tetanus antitoxin levels declined with age. It appears that most 50 years of age and older adults do not have protective levels of tetanus antitoxin because of inadequate vaccination coverage. There is a need to improve the immunity levels of this age group. It is recommended to vaccinate elderly people against tetanus.
Bleck TP. Clostridium tetani (tetanus). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas andBennett’s Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2010. p. 3091-6.
Karabay O, Ozkardes F, Tamer A, Karaarslan K. Tetanus immunity in nursing home residents of Bolu, Turkey. BMC Public Health 2005;5:5.
Oztürk A, Göahmetoğlu S, Erdem F, Mýsgüroğlu Alkan S. Tetanus antitoxin levels among adults over 40 years of age in Central Anatolia, Turkey. Clin Microbiol Infect 2003;9(1):33-8.
Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM,Sutter RW, Virella G. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995;332(12):761-6.
McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY,Wharton M. Serologic immunity to diphtheria and tetanusin the United States. Ann Intern Med 2002;136(9):660-6.
Maple PA, Jones CS, Wall EC, Vyseb A, Edmunds WJ, Andrews NJ, Miller E. Immunity to diphtheria and tetanus in England and Wales. Vaccine 2000;19(2-3):167-73.
Christenson B, Böttiger M. Epidemiology and immunity to tetanus in Sweden. Scand J Infect Dis 1987;19(4):429-35.
Gidding HF, Backhouse JL, Burgess MA, Gilbert GL. Immunity to diphtheria and tetanus in Australia: a nationalserosurvey. Med J Aust 2005;183(6):301-4.
Matousková I, Máchová L, Cízek L, Janoutová G, Hosková J, Janout V. Tetanus immunity in the elderly in the Czech Republic. Epidemiol Mikrobiol Imunol2007;56(1):10-3.
Janout V, Matouskova I, Machova L, Cizek L, Janoutova G, Hoskova J. Protection against tetanus in the aged people in the Czech Republic:cross-sectional study. Arch Gerontol Geriatr 2005;40(2):123-8.
World Health Organization (WHO) / The United Nations Children’s Fund (UNICEF) Immunization Summary: The 2011 edition (data through 2009). Immunization surveillance, assessment and monitoring, Data, statistics and graphics. [online] 2011 Jun [cited 2011 Jun 15]; Available from: URL:http://www.childinfo.org/files/32775_UNICEF.pdf
Vahdani P, Aminzadeh Z. Epidemiologic survey and clinical manifestation of Tetanus disease for 9 years (1992- 2001) in Loghman Hospital. Iran J Infect Dis Trop Med 2004;22:56-4.
Zarei S, Jeddi-Tehrani M, Akhondi MM, Zeraati H, Kheirkhah T, Ghazanfari M, Shokri F. Immunogenicity of a triple diphtheria-tetanus-whole cell pertussis vaccine in Iranian preschool children. Iran J Immunol 2007;4(2):101-9.
Ergönül O, Sözen T, Tekeli E. Immunity to tetanus among adults in Turkey. Scand J Infect Dis 2001;33(10):728-30.
Wu CJ, Ko HC, Lee HC, Tsai WC, Li MG, Pao YZ, Lee NY, Chang CM, Shih HI, Ko WC. Decline of tetanus antitoxin level with age in taiwan. J Formos Med Assoc 2009;108(5):395-401.
Centers for Disease Control (CDC). Tetanus: United States, 1987 and 1988. MMWR Morb Mortal Wkly Rep 1990;39(3):37-41.
Trollfors B, Knutsson N, Taranger J, Mark A, Bergfors E, Sundh V, Lagergård T. Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timingof a booster dose. Eur J Pediatr 2006;165(1):14-8.
Cavuslu S, Oncul O, Altunay H, Ozsoy MF, Kocak N.Seroprevalence of tetanus antibody in Turkish population and effectiveness of single-dose tetanus toxoid. Eur J Clin Microbiol Infect Dis 2003;22(7):431-3.
| Files | ||
| Issue | Vol 49, No 6 (2011) | |
| Section | Original Article(s) | |
| Keywords | ||
| Tetanus Immunity Older persons | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
